- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02097264
A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
A Randomised, Active Comparator, Double-blind, Multi Centre, Parallel, Phase 2a Trial, Investigating the Mechanism of Action, of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female age at least 18 and below or equal to 75 years at the time of signing informed consent
- A diagnosis of RA at least 6 months prior to screening visit, according to the American College of Rheumatology (EULAR/ACR 2010 criteria) or by standard criteria (ACR 1987) if diagnosis was made earlier than 2010
- Subjects with ACR global functional status of 1 to 3
- Active RA, characterised by: DAS28 (Disease Activity Score 28) (CRP (C-reactive protein)) above 4.5 and equal to or above 6 tender and equal to or above 6 swollen joints based on a 66/68 joint count
- Active Synovitis in at least two joints of the wrist and metacarpophalangeal joints, as assessed by high frequency Power Doppler ultrasound scan at screening and randomisation
Exclusion Criteria:
- Subjects with arthritis due to other autoimmune diseases than RA
- Body weight above 90.0 kg
- History of or current inflammatory joint disease other than RA (e.g. gout, psoriatic or reactive arthritis, Lyme disease, juvenile idiopathic arthritis, excluding secondary Sjogren syndrome and hypothyroidism)
- Any active or on-going bacterial infections within 4 weeks prior to screening visit, unless treated and resolved with appropriate therapy or any history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis)
- Subjects with malignancy within the previous 5 years with the exception of adequately treated and cured basal or squamous cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months prior to screening visit
- Female who is pregnant, breast feeding, intends to become pregnant or is of childbearing potential, not willing to use two highly effective contraceptive methods (adequate highlyeffective contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, sterilisation, intrauterine device or intrauterine system) one of which has to be a barrier method a barrier method of contraception (e.g. condom with spermicidal foam/gel/film/cream), for at least 16 weeks (approximately 5 half-lives) following the last dose of trial medication
- Male subjects who are sexually active and not surgically sterilised, who or whose partner are unwilling to use two different forms of highly effective contraception, one of which has to be a barrier method a barrier method of contraception (e.g. condom with spermicidal foam/gel/film/cream) for the duration of the trial and for at least 16 weeks (approximately 5 half-lives) following the last dose of trial medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Adalimumab
|
Solution for injection administered subcutaneously (s.c. - under the skin). 1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks).
Solution for injection administered subcutaneously (s.c. - under the skin).
Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c.
injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
|
Experimental: NNC0109-0012
|
Solution for injection administered subcutaneously (s.c. - under the skin).
240 mg NNC0109-0012 will be administered weekly for 12 weeks
Solution for injection administered subcutaneously (s.c. - under the skin). 1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the total histopathological synovitis score
Time Frame: Week 0, week 12
|
Week 0, week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in dynamic contrast enhanced MRI (DCE-MRI) measures of initial rate of enhancement (IRE)
Time Frame: Week 0, week 12
|
Week 0, week 12
|
Change in dynamic contrast enhanced MRI (DCE-MRI) measures of maximal enhancement (ME)
Time Frame: Week 0, week 12
|
Week 0, week 12
|
Changes in RA-MRI scores (RAMRIS (Rheumatoid arthritis magnetic resonance imaging)) of synovitis
Time Frame: Week 0, week 12
|
Week 0, week 12
|
Changes in RA-MRI scores (RAMRIS) of oedema
Time Frame: Week 0, week 12
|
Week 0, week 12
|
Changes in RA-MRI scores (RAMRIS) of erosion
Time Frame: Week 0, week 12
|
Week 0, week 12
|
Change in high frequency ultrasound with Power Doppler measures of total synovitis
Time Frame: Week 0, week 12
|
Week 0, week 12
|
Change in high frequency ultrasound with Power Doppler measures of total tenosynovitis scores
Time Frame: Week 0, week 12
|
Week 0, week 12
|
Change in disease activity 28 - C-reactive protein (DAS28 (CRP)
Time Frame: Week 0, week 12
|
Week 0, week 12
|
Incidence of Adverse Events (AE)
Time Frame: Week 0, week 24
|
Week 0, week 24
|
Incidence of local intolerability at the injection site
Time Frame: Week 0, week 24
|
Week 0, week 24
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN8226-4064
- 2013-001492-20 (EudraCT Number)
- U1111-1141-3512 (Other Identifier: WHO)
- REec-2014-0740 (Registry Identifier: Spanish Register of Clinical Studies (REec))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Singapore National Eye CentreCompletedIntraocular Inflammation in ChildrenSingapore
Clinical Trials on NNC0109-0012
-
Novo Nordisk A/STerminatedInflammation | Rheumatoid ArthritisUnited States, Mexico, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Hungary, Poland, United Kingdom
-
Novo Nordisk A/STerminatedInflammation | Rheumatoid ArthritisUnited States, Mexico, Russian Federation, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Poland, Ukraine, Hungary
-
Novo Nordisk A/SCompletedInflammation | Rheumatoid ArthritisUnited Kingdom, Italy, Poland, Portugal, Spain, Germany, Czech Republic, Romania
-
M.D. Anderson Cancer CenterWithdrawnCarcinoid Syndrome | Advanced Neuroendocrine Neoplasm
-
Mridula George, MDNational Cancer Institute (NCI); Incyte Corporation; Oncolytics BiotechRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Triple-negative Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGlioma | Recurrent Childhood Medulloblastoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Diffuse Intrinsic Pontine Glioma | Refractory Brain Neoplasm | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Glioblastoma | Recurrent Primitive Neuroectodermal Tumor | Childhood Astrocytoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Mucosal Melanoma | Iris Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanoma | Recurrent... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedGlioblastoma | Gliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain Neoplasm | Mixed GliomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Metastatic Malignant Neoplasm in the LungUnited States, Canada, Puerto Rico, Australia, New Zealand
-
University of WashingtonNational Cancer Institute (NCI); University of Wisconsin, MadisonActive, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | HER2/Neu Negative | Stage III Breast Cancer | No Evidence of Disease | One or More Positive Axillary NodesUnited States